Belite Bio, Inc
BLTE
$155.54
$3.572.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 12/31/2024 | 12/31/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.32M | -- | -10.10M | -10.10M | -- |
| Total Depreciation and Amortization | -163.00K | -- | -163.00K | 118.00K | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.84M | -- | 3.24M | 2.96M | -- |
| Change in Net Operating Assets | 1.26M | -- | 2.42M | 2.42M | -- |
| Cash from Operations | -10.39M | -- | -4.60M | -4.60M | -- |
| Capital Expenditure | -178.00K | -- | 0.00 | 0.00 | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -303.56M | -- | -26.01M | -26.01M | -- |
| Cash from Investing | -303.73M | -- | -26.01M | -26.01M | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 132.99M | -- | 39.16M | 39.16M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 377.13M | -- | 613.00K | 613.00K | -- |
| Cash from Financing | 510.12M | -- | 39.78M | 39.78M | -- |
| Foreign Exchange rate Adjustments | -101.00K | -- | -277.00K | -277.00K | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 195.90M | -- | 8.88M | 8.88M | -- |